for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biocon Ltd

BION.BO

Latest Trade

291.70INR

Change

-1.30(-0.44%)

Volume

198,906

Today's Range

290.55

 - 

295.00

52 Week Range

211.30

 - 

341.43

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
293.00
Open
294.55
Volume
198,906
3M AVG Volume
84.56
Today's High
295.00
Today's Low
290.55
52 Week High
341.43
52 Week Low
211.30
Shares Out (MIL)
1,200.00
Market Cap (MIL)
346,116.90
Forward P/E
36.66
Dividend (Yield %)
0.17

Next Event

Q3 2020 Biocon Ltd Earnings Release

Latest Developments

More

Biocon, Equillium Expand Exclusive Licensing Deal For Itolizumab To Include Australia And New Zealand

FDA Approves First Generics Of Gilenya

Biocon Say Siddharth Mittal Takes Over As CEO, Joint MD

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biocon Ltd

Biocon Limited is a biopharmaceutical company. The Company focuses to reduce therapy costs of chronic diseases like autoimmune, diabetes, and cancer. Through its products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. The Company has developed and taken a range of Novel Biologics, Biosimilars, differentiated Small Molecules and affordable Recombinant Human Insulin and Analogs from Lab to Market. The Company’s brands include INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab) and ALZUMAb (Itolizumab), an anti-CD6 monoclonal antibody. It has a pipeline of Biosimilars and Novel Biologics at various stages of development, including Insulin Tregopil, an oral insulin analog.

Industry

Biotechnology & Drugs

Contact Info

20th KM, Hosur Road, Electronics City

+91.80.28082808

http://www.biocon.com/

Executive Leadership

Kiran Mazumdar-Shaw

Executive Non-Independent Chairman of the Board, Managing Director

Siddharth Mittal

Chief Executive Officer, Joint Managing Director

John Mccallum Marshall Shaw

Non-Executive Vice Chairman of the Board

Peter James Jonathan Bains

CEO & Director of Syngene

Abhijit Barve

President - Research & Development

Key Stats

2.50 mean rating - 20 analysts
Sell
Hold
Buy
Revenue (MM, INR)

2017

38.5K

2018

41.3K

2019

55.1K

2020(E)

67.7K
EPS (INR)

2017

185.820

2018

12.540

2019

5.965

2020(E)

7.974
Price To Earnings (TTM)
40.53
Price To Sales (TTM)
5.67
Price To Book (MRQ)
5.50
Price To Cash Flow (TTM)
23.70
Total Debt To Equity (MRQ)
35.00
LT Debt To Equity (MRQ)
27.72
Return on Investment (TTM)
11.04
Return on Equity (TTM)
7.88

Latest News

Latest News

India's Biocon quarterly profit more than doubles, beats estimate

Indian biotechnology firm Biocon Ltd's quarterly profit more than doubled, handily beating analysts' estimates, largely driven by strong performance of its biologics businesses.

CORRECTED-India's Biocon Q2 profit surges on one-off gain

Indian biotechnology company Biocon Ltd posted an over five-fold rise in second-quarter profit on Thursday, as the company recorded a one-off gain of 1.89 billion rupees ($25.79 million).

CORRECTED-India's Biocon June-qtr profit jumps 47 pct, beats estimates

India's Biocon Ltd reported a 47 percent rise in June-quarter profit on Thursday, helped by higher income from its biologics and research services businesses.

BRIEF-India's Biocon Says USFDA, European Regulator Issue Observations On Bangalore Plant

* SAYS US-FDA COMPLETED PRE-APPROVAL INSPECTION OF STERILE DRUG PRODUCT PLANT IN BANGALORE AND ISSUED A FORM 483 WITH 7 OBSERVATIONS

BRIEF-Biocon Q4 Net Profit Up 2 Percent

* Q4 NET PROFIT UP 2 PERCENT TO 1.30 BILLION RUPEES; Q4 TOTAL REVENUE 12.37 BILLION RUPEES VERSUS 9.74 BILLION RUPEES YEAR-AGO Further company coverage: (Reuters.Briefs@thomsonreuters.com)

India's Biocon Q4 profit rises 2.2 pct

Biocon Ltd, India's biggest biotechnology company, posted a marginal 2.2 percent rise in net profit on Thursday.

BRIEF-Mylan, Biocon Seek To Accelerate Introduction Of Adalimumab Biosimilar In EU

* MYLAN, BIOCON SEEK TO ACCELERATE INTRODUCTION OF ADALIMUMAB BIOSIMILAR IN EU Source text - https://bit.ly/2IIPzM6 Further company coverage:

BRIEF-Mylan, Biocon get approvals from European Commission, TGA Australia for Semglee, Biosimilar Insulin Glargine

* MYLAN AND BIOCON RECEIVE APPROVALS FROM THE EUROPEAN COMMISSION AND TGA AUSTRALIA FOR SEMGLEE™, BIOSIMILAR INSULIN GLARGINE Source text for Eikon: Further company coverage:

BRIEF-India's Biocon ‍Says U.S. FDA Completed Pre-Approval Inspection At Malaysia Unit ​

* U.S. FDA COMPLETED PRE-APPROVAL INSPECTION AT MALAYSIA FACILITY AND ISSUED FORM 483 WITH 6 OBSERVATIONS Source text - http://bit.ly/2EUL56I Further company coverage:

BRIEF-Cytosorbents Expands Its Partnership With Biocon To Launch Cytosorb In Malaysia

* CYTOSORBENTS EXPANDS ITS PARTNERSHIP WITH BIOCON TO LAUNCH CYTOSORB® IN MALAYSIA

BRIEF-Mylan And Biocon Receive Positive CHMP Opinion For Semglee, Biosimilar Insulin Glargine

* MYLAN AND BIOCON RECEIVE POSITIVE CHMP OPINION FOR SEMGLEE™, BIOSIMILAR INSULIN GLARGINE

India's Biocon Q3 profit plunges 46 pct

Biocon Ltd, India's biggest biotechnology firm, posted a 46 percent fall in third-quarter profit on Wednesday hurt by an increase in interest and depreciation costs related to its Malaysia operations.

BRIEF-India's Biocon Dec-Qtr Consol Profit Down About 46 pct

* DEC QUARTER CONSOL PROFIT 919 MILLION RUPEES VERSUS 1.71 BILLION RUPEES LAST YEAR

BRIEF-Biocon Announces Exclusive Global Collaboration With Sandoz On Next-Generation Biosimilars

* ANNOUNCES EXCLUSIVE GLOBAL COLLABORATION WITH SANDOZ ON NEXT-GENERATION BIOSIMILARS'

BRIEF-Biocon And Mylan's Biosimilar Trastuzumab Gets Approval From ANVISA, Brazil

* CO AND MYLAN'S BIOSIMILAR TRASTUZUMAB RECEIVES APPROVAL FROM ANVISA, BRAZIL THROUGH THEIR PARTNER LIBBS

BRIEF-Biocon Says Has Paid Facility Fee For Its API Facility To U.S. FDA

* CLARIFIES ON NEWS ITEM REGARDING CO'S NAME ON FDA LIST FOR NOT PAYING FACILITY FEE

BRIEF-India's Biocon To Transfer Biosimilar Business Via Slump Sale As 'Going Concern' To Biocon Biologics India

* INDIA'S BIOCON SAYS TO TRANSFER BIOSIMILAR BUSINESS THROUGH SLUMP SALE AS 'GOING CONCERN' TO BIOCON BIOLOGICS INDIA - EXCHANGES

BRIEF-EMA Accepts Marketing Authorization Applications For Mylan And Biocon's Proposed Biosimilars

* EUROPEAN MEDICINES AGENCY ACCEPTS MARKETING AUTHORIZATION APPLICATIONS FOR MYLAN AND BIOCON'S PROPOSED BIOSIMILARS TRASTUZUMAB AND PEGFILGRASTIM

BRIEF-Biocon ‍launches Krabeva in India​

* Launches Krabeva - biosimilar Bevacizumab for treating several types of cancer in India

BRIEF-Biocon says co's facility receives EIR with VAI status​

* Says Biocon's facility receives EIR with vai status Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up